ArticleRespiratory research2025
The P4HA1/HIF1α feedback loop modulates endothelial dysfunction in pulmonary hypertension.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- m6A target gene signatures reveal immune-related diagnostic biomarkers in systemic sclerosis-associated pulmonary arterial hypertension.Journal of thoracic disease · 2026Article
- The Role of Platelets in Pulmonary Hypertension: From Activation to Pulmonary Vascular Remodeling-A Review Article.Biomedicines · 2026Review
- Snhg18 promotes hypoxic pulmonary hypertension by enhancing glycolysis.Respiratory research · 2026Article
- Emerging significance of E3 ubiquitin ligases and Deubiquitinases in pulmonary hypertension.Molecular medicine (Cambridge, Mass.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPulmonary hypertension is a severe vascular disease characterised by pulmonary arterial remodeling and right heart failure. However, the role of the glycolytic protein P4HA1 in its pathogenesis remains elusive.
methodsRNA-seq analysis was performed on hypoxic human pulmonary artery endothelial cells, and P4HA1 expression was validated in PH animal models. In vitro, P4HA1 knockdown was used to assess its effects on glycolysis, proliferation, and migration. Mechanistic studies included HIF1α transcriptional regulation and P4HA1-mediated HIF1α stabilization via reduced ubiquitination. AAV9-shP4HA1 was employed to assess P4HA1's function in pulmonary vascular remodeling in vivo.
resultsP4HA1 was significantly upregulated in human pulmonary arterial endothelial cells (HPAECs) exposed to hypoxia. Mechanistic investigations revealed that HIF1α transcriptionally activates P4HA1 expression, while P4HA1 reciprocally stabilizes HIF1α by attenuating its ubiquitin-mediated degradation, thereby establishing a self-amplifying signaling loop. Functional studies demonstrated that P4HA1 knockdown effectively suppressed hypoxia-induced glycolytic reprogramming, inhibited cellular proliferation, and impaired migratory capacity in HPAECs. Consistent with these in vitro findings, endothelial-specific P4HA1 knockdown in vivo significantly attenuated hypoxia-induced pulmonary vascular remodeling and improved right ventricular function in a mouse PH model.
conclusionsOur studty identify P4HA1 as a novel contributor to PH pathogenesis and suggest that targeting the P4HA1/HIF1α axis may offer a promising therapeutic approach for pulmonary hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.